Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Phase 3

Conditions: Lung Neoplasms

Interventions: Drug: Gefitinib
Drug: Pemetrexed

First Posted Date: 2015-08-10

Last Posted Date: 2015-08-10

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 220

Registration Number: NCT02518802

Locations: 🇨🇳
Tangdu Hospital of the Fourth Millitary Medical University, Xi'an, Shaanxi, China

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

Phase 2

Terminated

Conditions: Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions: Drug: Pemetrexed
Drug: Afatinib

First Posted Date: 2015-07-02

Last Posted Date: 2018-01-09

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 4

Registration Number: NCT02488694

Locations: 🇩🇪
Universitätsklinikum Essen, Essen, Germany

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Vinorelbine
Drug: Docetaxel
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-07-01

Last Posted Date: 2024-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1280

Registration Number: NCT02486718

Locations: 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷
Hôpital Universitaire Dupuytren, Limoges, France

and more 225 locations

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Carboplatin
Drug: Ipilimumab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2015-06-23

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2748

Registration Number: NCT02477826

Locations: 🇺🇸
Local Institution - 0017, San Francisco, California, United States
🇺🇸
Local Institution - 0115, Saint Louis, Missouri, United States
🇺🇸
Local Institution - 0014, Cleveland, Ohio, United States

and more 287 locations

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Viagenpumatucel-L
Drug: Nivolumab
Drug: Pembrolizumab
Drug: Pemetrexed

First Posted Date: 2015-05-08

Last Posted Date: 2023-09-21

Lead Sponsor: Heat Biologics

Target Recruit Count: 121

Registration Number: NCT02439450

Locations: 🇺🇸
UC San Diego, La Jolla, California, United States
🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸
Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States

and more 13 locations

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Clinical Stage III Cutaneous Melanoma AJCC V8
Clinical Stage IV Cutaneous Melanoma AJCC V8
Fallopian Tube Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Metastatic Renal Cell Carcinoma
Ovarian Carcinoma
Pathologic Stage III Cutaneous Melanoma AJCC V8

Interventions: Drug: Carboplatin
Drug: Eribulin
Drug: Fluorouracil
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Capecitabine
Biological: Pembrolizumab
Drug: Olaparib
Biological: Nivolumab
Biological: Ipilimumab
Drug: Selinexor
Drug: Doxorubicin
Drug: Topotecan
Drug: Pemetrexed
Drug: Irinotecan Hydrochloride
Drug: Oxaliplatin
Drug: Leucovorin Calcium

First Posted Date: 2015-04-17

Last Posted Date: 2024-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 221

Registration Number: NCT02419495

Locations: 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 2 locations

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Drug: Carboplatin
Drug: Cisplatin
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-04-06

Last Posted Date: 2023-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 572

Registration Number: NCT02409342

Locations: 🇫🇷
Centre D'oncologie de Gentilly, Nancy, France
🇫🇷
Centre Hospitalier Regional Sud Reunion, Saint-pierre, France
🇧🇷
Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil

and more 139 locations

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Icotinib
Drug: Pemetrexed
Radiation: Thoracic radiotherapy(TRT)
Drug: Carboplatin

First Posted Date: 2015-04-02

Last Posted Date: 2015-04-02

Lead Sponsor: People's Hospital of Guangxi

Target Recruit Count: 80

Registration Number: NCT02407366

Locations: 🇨🇳
The people's Hospital of the Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Device: NovoTTF-100L device
Drug: Pemetrexed
Drug: Cisplatin or Carboplatin

First Posted Date: 2015-03-25

Last Posted Date: 2018-09-25

Lead Sponsor: NovoCure Ltd.

Target Recruit Count: 82

Registration Number: NCT02397928

Locations: 🇵🇱
Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland
🇮🇹
A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy
🇳🇱
Erasmus Mc, Rotterdam, Netherlands

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy